An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials ...

Opthea Limited (OPT), a biopharmaceutical firm, has decided to discontinue its Phase 3 clinical program for sozinibercept in treating wet age-related macular degeneration (wet AMD). This decision ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...